Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.36 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29783216 | 1.00 | HPGD (0.39) | HPGDALDH1A1CYP4F2CYP4A11NPC1 | |
| SCHEMBL17704659 | 0.83 | ESR1 (0.48) | HPGDALDH1A1NPC1NR2F2NOD2 | |
| SCHEMBL10257025 | 0.81 | HPGD (0.43) | HPGDALDH1A1NPC1TRPA1CYP1A2 | |
| SCHEMBL308275 | 0.81 | ALDH1A1 (0.39) | ALDH1A1CYP4F2CYP4A11NPC1TSHR | |
| SCHEMBL29427134 | 0.81 | ALDH1A1 (0.39) | ALDH1A1CYP4F2CYP4A11NPC1TSHR | |
| SCHEMBL539541 | 0.80 | ALDH1A1 (0.40) | ALDH1A1CYP4F2CYP4A11NPC1TSHR | |
| SCHEMBL29559999 | 0.80 | ALDH1A1 (0.40) | ALDH1A1CYP4F2CYP4A11NPC1TSHR | |
| SCHEMBL3398586 | 0.79 | HRH3 (0.39) | HPGDALDH1A1GAAMAPT | |
| SCHEMBL11495289 | 0.79 | HPGD (0.38) | HPGDALDH1A1NPC1NR2F2NOD2 | |
| SCHEMBL1363463 | 0.79 | HRH3 (0.39) | HPGDALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727654-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | Mariana Oncology Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4727655-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | Mariana Oncology Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4727653-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | Mariana Oncology Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250296959-A1 | B7-H3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC (US) | 2025-09-25 | — | — | US | disclosed |
| US-20250205373-A1 | ENRICHED AND STABLE RADIOLIGAND THERAPY FORMULATIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | MARIANA ONCOLOGY INC (US) | 2025-06-26 | — | — | US | disclosed |
| WO-2025122615-A1 | ENRICHED AND STABLE RADIOLIGAND THERAPY FORMULATIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | MARIANA ONCOLOGY INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| US-20250186541-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC (US) | 2025-06-12 | — | — | US | disclosed |
| EP-4565258-A2 | COMPOSITIONS FOR THE TREATMENT OF DISEASE | Sightstream Biotherapeutics, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20250179691-A1 | MULTIVALENT GLYCOPEPTIDES THAT TIGHTLY BIND TO CARBOHYDRATE-BINDING MONOCLONAL ANTIBODY FAMILY PGT128 | BRANDEIS UNIVERSITY (US) | 2025-06-05 | — | — | US | disclosed |
| US-12247320-B2 | Multivalent glycopeptides that tightly bind to carbohydrate-binding monoclonal antibody family PGT128 | BRANDEIS UNIVERSITY (US) | 2025-03-11 | — | — | US | disclosed |
| EP-1294789-A1 | REVERSIBLE CROSSLINKED POLYMERS, BENZYL CROSSLINKERS AND METHOD | BATTELLE MEMORIAL INSTITUTE (US) | 2003-03-26 | — | — | EP | disclosed |
| US-6479498-B1 | COMPRISE 2-10 SODIUM CHANNEL LIGANDS COVALENTLY CONNECTED BY A LINKER OR LINKERS | THERAVANCE, INC. | 2002-11-12 | — | — | US | disclosed |
| US-6420354-B1 | Sodium channel drugs and uses | ADVANCED MEDICINE, INC. | 2002-07-16 | — | — | US | disclosed |
| WO-2001092366-A1 | REVERSIBLE CROSSLINKED POLYMERS, BENZYL CROSSLINKERS AND METHOD | BATTELLE MEMORIAL INSTITUTE (US) | 2001-12-06 | — | — | WO | disclosed |
| WO-2001090101-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-11-29 | — | — | WO | disclosed |
| EP-1112998-A1 | AMINE DERIVATIVES | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2001-07-04 | — | — | EP | disclosed |
| EP-0318935-B1 | Substituted alpha-amino acids having pharmaceutical activity | WARNER LAMBERT CO (US) | 1995-02-01 | — | — | EP | disclosed |
| US-5175153-A | Antiischemic agents or antiepileptic agents | WARNER-LAMBERT COMPANY (US) | 1992-12-29 | — | — | US | disclosed |
| EP-0421436-A2 | Substituted carboxytetrahydroisoquinolines and derivatives thereof having pharmaceutical activity | WARNER-LAMBERT COMPANY (US) | 1991-04-10 | — | — | EP | disclosed |
| EP-0318935-A2 | Substituted alpha-amino acids having pharmaceutical activity | WARNER-LAMBERT COMPANY (US) | 1989-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179691-A1 | MULTIVALENT GLYCOPEPTIDES THAT TIGHTLY BIND TO CARBOHYDRATE-BINDING MONOCLONAL ANTIBODY FAMILY PGT128 | CSGALNACT1, STT3A, STT3B | HPGD 4402/4885ALDH1A1 4633/4885CYP4F2 3507/4885 |
| US-20250186541-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | DLK1, DBNL, PDLIM5 | HPGD 4598/4885ALDH1A1 4342/4885CYP4F2 4796/4885 |
| US-20250296959-A1 | B7-H3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | CD274, CD44, CD74 | HPGD 2692/4885ALDH1A1 3394/4885CYP4F2 4780/4885 |
| US-20250205373-A1 | ENRICHED AND STABLE RADIOLIGAND THERAPY FORMULATIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | ASGR1, GPR119, LDLR | HPGD 1338/4885ALDH1A1 2722/4885CYP4F2 2200/4885 |
| US-12247320-B2 | Multivalent glycopeptides that tightly bind to carbohydrate-binding monoclonal antibody family PGT128 | CSGALNACT1, STT3A, GALNT14 | HPGD 4216/4885ALDH1A1 4399/4885CYP4F2 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.